ALK and non-small cell lung carcinoma: Among these ICIs, pembrolizumab, either as monotherapy in patients with NSCLC whose tumors express high PD-L1 (≥50% total progression score, TPS) by IHC and lack EGFR or ALK genomic tumor aberrations, or in combination with pemetrexed and carboplatin in patients with non-squamous NSCLC whose tumors express no or low PD-L1 (i.e., 0–49% TPS), has been demonstrated to improve OS compared to standard-of-care chemotherapy as first-line systemic therapy [56,57,58,59,60,61].